One of the things we are most proud of at @IsomorphicLabs is the culture we’ve built alongside our frontier AI. Our collaborative approach is transforming how we design new drugs and how medicine will help and heal people.The video below captures a bit of that energy and the Isos behind the breakthroughs, and we’re looking for more brilliant people to join us.Head to the comments to explore our open roles. ...

It’s @JPM Healthcare Week and today @IsomorphicLabs' President @maxjaderberg will join a panel hosted by @Benchling, on how scientific models are reshaping biotech R&D. If you’re in town, come along to hear Max share how Iso’s unified drug design engine could help accelerate treatments across many diseases. Head to the comments for the link. #JPMHC26 ...

In less than a week, our CTO @SergeiIakhnin will open @BioTechX_ EU with his keynote: "AI Models from Atoms to Humans: the Era of Rational In Silico Drug Design."Join him in Basel on October 6th, at 9am CEST to explore how advanced AI is already reinventing drug discovery, and his vision for a future where it accelerates breakthroughs that move us closer to solving all disease. ...

Drug Development & AI - Isomorphic Labs is using AI models to tackle challenging diseases, including cancers [1] - The company has a generalisable drug design engine to tackle a range of different cancers [1] Company Strategy - Isomorphic Labs aims to tackle multiple cancers rather than focusing on one program at a time [1]

AI in Drug Discovery - Isomorphic Labs 致力于从根本上重新思考药物发现，利用人工智能技术 [1] - 该公司正在探索人工智能在应对疾病方面的可能性 [1] - 讨论了人工智能在生物学中的应用 [1] - 重点介绍了 AlphaFold 3 在药物发现中的作用 [1] Future of Drug Development - 探讨了人机协作在药物设计中的应用 [2] - 讨论了药物设计面临的挑战 [2] - 探索了超越动物模型的药物研发方法 [2] - 展望了人工智能药物的未来 [2]

Event Announcement - Isomorphic Labs 团队将参加 6 月 2 日至 3 日在瑞士巴塞尔诺华园区举行的 Empowering Women in Organic Chemistry Europe Conference [1] Company Focus - Isomorphic Labs 正在推动 AI 优先的药物设计方法 [1] Call to Action - 鼓励参会者与 Isomorphic Labs 的代表联系 [1]

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.”On Sequoia Capital’s Training Data podcast, our Chief AI Officer @MaxJaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines.Listen to the full podcast at the link below:https://t.co/0ve7jAAZxN ...